EMVision CEO, Dr Ron Weinberger commented: “It’s an honour to have received this funding considering
the large number of applicants. I believe it is recognition of our unique technology but more importantly, the
understanding by the selection panel of the potential to revolutionise stroke imaging and treatment at the
Point-of-Care. The funding will be instrumental in driving our clinical trials. We look forward to the
connectivity that this program provides us to the NSW healthcare system.”
It is the NOVEL technology.
EMVision CEO, Dr Ron Weinberger commented: “It’s an honour to...
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
